PM310: the Next Generation of Anti-Amyloid Antibodies that Avoid ARIA to Improve Safety
Time: 12:00 pm
day: Clinical & Commercial Track AM
Details:
- Oligomer specificity can be generated
- Specificity for oligomers will reduce competition by Amyloid beta monomers
- Specificity for oligomers will improve safety by reducing ARIA
